uniQure N.V (UQ1) - Total Liabilities
Based on the latest financial reports, uniQure N.V (UQ1) has total liabilities worth €629.36 Million EUR (≈ $735.79 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
uniQure N.V - Total Liabilities Trend (2016–2025)
This chart illustrates how uniQure N.V's total liabilities have evolved over time, based on quarterly financial data. See uniQure N.V (UQ1) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
uniQure N.V Competitors by Total Liabilities
The table below lists competitors of uniQure N.V ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hunan TV & Broadcast Intermediary Co Ltd
SHE:000917
|
China | CN¥5.55 Billion |
|
Macmahon Holdings Ltd
AU:MAH
|
Australia | AU$992.39 Million |
|
Azad Engineering Limited
NSE:AZAD
|
India | Rs6.71 Billion |
|
ShenZhen Kondarl Group Co Ltd
SHE:000048
|
China | CN¥6.32 Billion |
|
Sihui Fuji Electronics Technology Co Ltd
SHE:300852
|
China | CN¥690.98 Million |
|
Changbai Mountain Tourism Co Ltd
SHG:603099
|
China | CN¥289.34 Million |
|
Chagee Holdings Limited American Depositary Shares
NASDAQ:CHA
|
USA | $3.89 Billion |
|
Shanxi Huaxiang Group Co Ltd
SHG:603112
|
China | CN¥2.20 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down uniQure N.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of uniQure N.V.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.81 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how uniQure N.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for uniQure N.V (2016–2025)
The table below shows the annual total liabilities of uniQure N.V from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €626.01 Million ≈ $731.87 Million |
+11.13% |
| 2024-12-31 | €563.29 Million ≈ $658.54 Million |
-9.73% |
| 2023-12-31 | €624.02 Million ≈ $729.54 Million |
+172.55% |
| 2022-12-31 | €228.96 Million ≈ $267.67 Million |
+7.29% |
| 2021-12-31 | €213.40 Million ≈ $249.49 Million |
+121.17% |
| 2020-12-31 | €96.49 Million ≈ $112.81 Million |
-23.16% |
| 2019-12-31 | €125.57 Million ≈ $146.81 Million |
+33.16% |
| 2018-12-31 | €94.30 Million ≈ $110.25 Million |
-21.60% |
| 2017-12-31 | €120.28 Million ≈ $140.63 Million |
-5.01% |
| 2016-12-31 | €126.63 Million ≈ $148.05 Million |
-- |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more